Tuesday, May 27, 2008

Something Beautiful

Please take a look at my dear friend, Deb's, blog.
She is fighting a recurrence and has just had her beautiful head decorated with a henna design...
It looks great and she is one of the nicest people you will ever meet.
Click HERE to see how great she is

Friday, May 9, 2008


The following report was just released.

It confirms what many doctors and researchers already knew: breast cancer in young women grows fast. Please urge every young woman in your life to get a baseline mammogram starting at AGE 30. NOT AGE 40.

Read this all the way through and it will tell you why it is so vital that young women need to know immediately if there is something growing in their breasts. However, the American Cancer Society has an expert at the end of this article stating that a woman should start screening at age 40.

This has to change. NOW.

I have seen TOO MANY WOMEN in their 30s and early 40s die because of this advice. They didn't get a mammogram, didn't think they needed one yet, or were told by their doctors they were "too young to get cancer."

Breast Cancer Tends to Grow Faster in Younger Women

By Steven Reinberg, HealthDay Reporter

posted: 08 May 2008 10:54 am ET

(HealthDay News) -- While the rate at which breast cancer tumors grow varies among patients, that growth tends to be faster among younger women, Norwegian researchers report.

These findings may help in planning and evaluating screening programs, clinical trials and other studies, the researchers say.

Using a new mathematical model, the scientists were also able to estimate the numbers of breast cancers detectable by mammography. This is a new approach to estimating the growth rate of tumors and the ability of mammograms to find them.

"There are enormous implications for the sensitivity of breast cancer screening programs," lead researcher Harald Weedon-Fekjr, of the Department of Etiological Research, Cancer Registry of Norway, said in a statement.

"We found that mammography screen test sensitivity increases sharply with increased tumor size, as one might expect. Detection rates are just 26 percent for a 5 millimeter tumor but increase to 91 percent once a tumor is 10 millimeter in size," he added.

The report was published in the May 8 issue of the online journal Breast Cancer Research.

In the study, Weedon-Fekjr, and colleagues tested their model using mammography results from 395,188 women aged 50 to 69.

The researchers found that the growth rate of tumors varied significantly between patients. About one in 20 tumors doubled in size, from 10 to 20 millimeters in just over a month. However, a similar number of tumors took more than six years to double in size.

Based on this finding, Weedon-Fekjr's team estimated that it takes an average of 1.7 years for tumors to double in size. Moreover, tumor growth appeared to be faster among younger women and slowed as women aged, the researchers noted.

"Tumor growth and test sensitivity estimates can be directly linked to tumor size in a full population study, resulting in very useful growth estimates directly connected to a biologically relevant measure," the researchers wrote.

"Tumor growth seems to vary greatly between tumors, with higher growth rates among younger women. Most tumors become visible at screening when they reach a diameter of 5 millimeters to 10 millimeters," they concluded.

One expert thinks this study again confirms the need for women to have a mammogram every year.

"This study continues to prove why we need to screen women every year, starting at age 40," said Debbie Saslow, director of breast and gynecologic cancer at the American Cancer Society.*

This is another study that shows that tumors grow faster in younger women, Saslow said. "It just doesn't make sense to have guidelines that say younger women should be screened every one to two years and every year as they get older," she said.


*Is this woman kidding?

Thursday, May 8, 2008

Where's Our Little Blue Pill?

I did some research today. The companies that make Viagra and Cialis, Ely Lilly and Pfizer, both spent $90 million dollars on advertising - in ONE year. The Levitra folks sponsored NFL games to the tune of $18 million dollars last season.

They are sure working hard to get the message out: "Men, we can make your lives even better!"

Let's forget about what cancer researchers could do with an extra $200 million dollars this year. Let's talk about what breast cancer treatment does to women.

First, we lose our hair. It grows back. Eventually. Some of us lose our breasts. They rebuild them. Eventually. Then, if our cancer is estrogen dependent, they give us pills to remove every last trace of estrogen in our bodies. Leaving us in a state that is normally experienced by octogenarians.

But we are not octogenarians. Some of us are in our thirties, forties and fifties... we are nowhere near menopause and have a lot of living yet to do. But in an estrogen depleted state it makes our bodies shut down. Some women are debilitated by the body aches and pains these pills cause. Some have sexual dysfunction to such a degree, sex is too painful to even think about, much less enjoy.

And there they are.... singing away..... "Viva, Viagra!" on the TV.

I have one question. Just one.

Do you think if men had to have all their testosterone turned off in order to survive and the ability to have normal sexual relations was suddenly impaired, there would be teams of scientists, researchers and inventors combing the globe to find a solution?

What do you think?

There are ways a woman can compensate without adding deadly hormones back to our bodies. But the system is imperfect to say the least. I guess it really doesn't matter to Ely Lilly and Pfizer. There are only over two million women dealing with this right now and 250,000 women being diagnosed with breast cancer every year.

Sunday, May 4, 2008


From the IT'S ABOUT DAMN TIME file I am VERY HAPPY to post this news release!

'Promise Grants' Offer Individuals, Corporations Unique Opportunities to

Invest in Significant Collaborative Research Ventures

DALLAS, April 21 /PRNewswire/ -- Susan G. Komen for the Cure(R), the

world's largest breast cancer organization, today announced the awarding of more than $100 million in research grants, representing the largest single-year investment in research in the organization's 26-year history and a 30 percent increase over last year's award total of $77 million. The 2008 grants slate moves Komen for the Cure closer to accomplishing its goal
of investing another $2 billion in breast cancer research and community health programs by 2017.

With this year's slate of 143 grants, Komen for the Cure has fully activated new funding mechanisms designed to speed the discovery and delivery of the cures for breast cancer. The 2008 slate funds projects designed to promote breast cancer research collaboration and cost
efficiencies, arrive at reliable and replicable research results more quickly, motivate bright young investigators to commit to breast cancer research careers and keep career researchers intensely focused on breast cancer.

"We've made it clear that our money will fund projects that focus on ways to significantly reduce breast cancer incidence and mortality within the next ten years," said Susan G. Komen for the Cure President and CEO Hala Moddelmog.

Specifically, Komen for the Cure is funding research initiatives exploring key breast cancer issues, including genetic risks, risk modulation, breast cancer stem cells, new targets for breast cancer therapies, therapeutic vaccines, treatment resistance, the molecular basis for chemotherapeutic response, strategies for the reduction of tumor progression, the role of micro-environments, the role of specific proteins in metastasis and treatments for bone metastasis.

An Overview of the 2008 Komen Grants Slate

Komen for the Cure expanded the types of requests for applications it issues from two to four this year and unveiled its new Promise Grants, which promote collaboration between basic and clinical researchers and different institutions to speed the discovery and delivery of the cures.

The awards provide up to $1.5 million per year over five years to address major issues critical to breast cancer. Promise Grants also provide unique opportunities for individuals or corporate partners to make direct investments in breast cancer research.

"Many individuals and corporate partners share Susan G. Komen for the Cure's sense of urgency in discovering and delivering the cures and finding ways to prevent breast cancer. Promise Grants allow donors to act on strong philanthropic impulses and essentially have a direct hand in writing a significant chapter in breast cancer research history," said Dr. Eric P. Winer, Susan G. Komen for the Cure's chief scientific advisor and leader of the organization's Scientific Advisory Board.

This year, Komen is funding seven Promise Grants focused on

estrogen-negative breast cancer, inflammatory breast cancer, the effects of obesity on the progression of breast cancer, molecular targets of treatment response, the development of hormonal therapies tailored to individual tumor and patient characteristics and the treatment of HER2-driven breast cancer.

Komen for the Cure is funding more than $35 million in Promise Grants for 2008. Along with the new Promise Grants, Komen for the Cure this year launched its Career Catalyst Research grants -- a new award mechanism that provides support for particularly promising young investigators to make the critical transition from training to scientific independence in breast cancer research. The awards offer $300,000 per year for two years, with option of an additional, performance-based award of $150,000 in year three.

Komen is funding $10.8 million in Career Catalyst Research grants for 2008. Susan G. Komen for the Cure continues to offer Post-doctoral Fellowships to support training for investigators who are in the early stages of their research careers. With awards of up to $60,000 per year for
two years and performance-based option for an additional $60,000 in year three, the awards are intended to attract new scientists to careers in breast cancer research. Komen for the Cure is funding just over $8 million in Post-doctoral Fellowship grants for 2008.

Komen for the Cure's scientific research portfolio continues to support Investigator Initiated Research projects by providing $600,000 per year for two to three years for the exploration of new ideas and approaches leading to reductions in breast cancer mortality and/or incidence within the next decade. Komen is investing more than $35 million in Investigator-initiated
research grants for 2008.Komen for the Cure also awarded a grant to the American Association of Clinical Oncology (ASCO) to create programs and provide grants that will support tangible improvements in access to and the delivery of cancer care, with special emphasis on addressing disparities in care and participation in clinical trials.

More information on grants awarded by Susan G. Komen for the Cure can be found at http://www.komen.org under "Grants Program." Details about all of Susan G. Komen for the Cure's 2008 research grants will be available online as contracts are finalized and signed.

It makes me want to go out and get myself a pink ribbon. Damn. THEY HEARD US! Want to donate? Make sure you are donating to THIS SPECIFIC PROGRAM. For example, "Komen for the Cure Triple Negative project."